Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Autologous adipose tissue-derived stromal vascular fraction (SVF) is an investigational cell therapy developed by the Dr. Himanshu Bansal Foundation for the treatment of fracture nonunion in long bones, such as the femur and tibia. The therapy involves the extraction of SVF from the patient's own adipose tissue via lipo-aspiration followed by non-enzymatic processing. This SVF contains a heterogeneous population of regenerative cells, including CD105+ and CD73+ mesenchymal stem cells (MSCs) and CD34+ hematopoietic cells. When injected percutaneously into the site of an atrophic nonunion under fluoroscopic guidance, these cells promote bone healing through their inherent osteogenic and angiogenic properties. This treatment is typically performed as an outpatient procedure and was evaluated in a retrospective study (NCT04340284).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous adipose tissue-derived stromal vascular fraction.